Deerfield-backed biotech emerges from stealth with gene therapy delivery platforms from Harvard and MIT
As a PhD student at Tufts, Dave Greenwald studied the use of adeno-associated virus (AAV) vectors to deliver gene therapies to people with retinitis pigmentosa, a group of rare genetic eye diseases that causes the retina to break down over time.
While he later left lab life, he now sits at the helm of Apertura Gene Therapy, a biotech that hopes to customize AAV vectors that are used widely in delivering most gene therapies. Apertura announced its launch from stealth with $67 million in Series A financing from Deerfield, where Greenwald is also a vice president of business development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
